Newsletter

Czar's Original

Total Labels 1
Approved 1
Expired 0

IMPEX CONSULTING GROUP, PETER V. WICK — CARMICHAEL, CA

Estonia, Russia Or The Russian Federation

About Czar's Original

Czar's Original is a vodka brand with origin states listed in the TTB COLA registry as Estonia, Russia, or the Russian Federation. The spirit is classified as vodka with an alcohol content in the 80 to 89 proof range. According to TTB public records, the brand maintains a single distinct product group currently available through major spirits retailers. The brand has received two total label approvals from the Alcohol and Tobacco Tax and Trade Bureau, with documented approval activity in 2020 and 2025. These registrations reflect the product's compliance with federal labeling and spirits classification standards. Czar's Original represents an entry in the vodka category, which remains one of the most widely consumed spirit categories in the United States. The brand's presence in the TTB COLA system indicates its legal status for sale and distribution within the United States market. As with all spirits products in this category, Czar's Original must meet federal standards for purity, proof declaration, and labeling accuracy before receiving approval for commercial sale.

Filter by:
Displaying 1 results
Label Name Spirit Type Status Approval Date Producer
Vodka 80-89 Proof Fb
Czar's Original

VODKA 80-89 PROOF FB

Vodka 80-89 Proof Fb Approved 2025-08-05 IMPEX CONSULTING GROUP, PETER V. WICK

Page 1 of 1

1

Czar's Original at a Glance

Czar's Original has 1 distinct product with 2 total TTB label approvals, including Vodka 80-89 Proof Fb. Labels approved between 2020-01-27 and 2025-08-05. Produced in Estonia, Russia Or The Russian Federation.

All information sourced from public TTB records.

Are you the owner or distributor of Czar's Original?

Claim this brand listing to update information or get featured. Contact team@buy.vodka.

Produced at Multiple Facilities

Related Brands

Related Questions

Browse All Labels

Stay informed

Newsletter coming soon.

Follow us on X for new approvals, launches, and industry intelligence.